Landoni M F, Lees P
Department of Veterinary Basic Sciences, Royal Veterinary College, Hatfield Herts, United Kingdom.
J Vet Pharmacol Ther. 1995 Dec;18(6):446-50. doi: 10.1111/j.1365-2885.1995.tb00624.x.
The bioavailability of S(+) and R(-) ketoprofen (KTP) in six horses was investigated after oral administration of the racemic (rac) mixture. Two oral formulations were studied, an oil-based paste containing micronised rac-KTP and powder from the same source in hard gelatin capsules, each at a dose rate of 2.2 mg/kg. For the oil-based paste two feeding schedules were used; horses were either allowed free access to food or access to food was restricted for 4 h before and 5 h after dosing. The drug in hard gelatin capsules was administered to horses with restricted access to food. After intravenous administration of rac-KTP, S(+) enantiomer concentrations exceeded those of the R(-) enantiomer. For S(+) and R(-)KTP, respectively, pharmacokinetic parameters were, t1/2 beta 0.99 +/- 0.14 h, 0.70 +/- 0.13 h; ClB 0.56 +/- 0.09, 0.92 +/- 0.20 L/h/kg; Vd(ss) 0.53 +/- 0.11, 0.61 +/- 0.10 L/kg. Following oral administration of rac-KTP as the oil-based paste to horses with free access to food, there were no detectable concentrations in plasma in three animals at any sampling time, while a fourth animal showed very low concentrations at two sampling times only. In the two remaining horses very low but detectable concentrations were present for 5 h. In the horses with restricted access to food, rac-KTP paste administration produced higher concentrations in plasma. However, bioavailability was very low, 2.67 +/- 0.43 and 5.75 +/- 1.48% for R(-) and S(+)KTP, respectively. When administered as pure drug substance in hard gelatin capsules, absorption of KTP was fairly rapid, but incomplete. Bioavailability was 50.55 +/- 10.95 and 54.17 +/- 9.9% for R(-) and S(+)KTP, respectively. This study demonstrates that rac-KTP had a modest bioavailability when administered as a micronised powder in hard gelatin capsules to horses with restricted access to food. When powder from the same source was administered as an oil-based paste, it was for practical purposes not bioavailable, regardless on the feeding schedule.
在给六匹马口服消旋酮洛芬(rac-KTP)混合物后,研究了S(+)和R(-)酮洛芬(KTP)的生物利用度。研究了两种口服制剂,一种是含有微粉化rac-KTP的油基糊剂,另一种是来自同一来源的硬明胶胶囊中的粉末,每种制剂的剂量率均为2.2mg/kg。对于油基糊剂,使用了两种喂食方案;马匹要么可以自由进食,要么在给药前4小时和给药后5小时限制进食。硬明胶胶囊中的药物是给进食受限的马匹服用的。静脉注射rac-KTP后,S(+)对映体浓度超过R(-)对映体浓度。对于S(+)和R(-)KTP,药代动力学参数分别为:t1/2β 0.99±0.14小时,0.70±0.13小时;ClB 0.56±0.09,0.92±0.20L/h/kg;Vd(ss) 0.53±0.11,0.61±0.10L/kg。给可以自由进食的马匹口服作为油基糊剂的rac-KTP后,三只动物在任何采样时间血浆中均未检测到浓度,而第四只动物仅在两个采样时间显示出非常低的浓度。在其余两匹马中,非常低但可检测到的浓度持续了5小时。在进食受限的马匹中,rac-KTP糊剂给药后血浆中产生的浓度更高。然而,生物利用度非常低,R(-)和S(+)KTP的生物利用度分别为2.67±0.43%和5.75±1.48%。当作为纯药物物质以硬明胶胶囊给药时,KTP的吸收相当迅速,但不完全。R(-)和S(+)KTP的生物利用度分别为50.55±10.95%和54.17±9.9%。这项研究表明,当以微粉化粉末形式在硬明胶胶囊中给进食受限的马匹服用时,rac-KTP的生物利用度适中。当将来自同一来源的粉末作为油基糊剂给药时,无论喂食方案如何,实际上都没有生物利用度。